We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study.
- Authors
Shimizu, Yuki; Kaji, Daisuke; Watanabe, Otoya; Yamaguchi, Kyosuke; Kageyama, Kosei; Taya, Yuki; Nishida, Aya; Ishiwata, Kazuya; Takagi, Shinsuke; Yamamoto, Hisashi; Mori, Yuki‐Asano; Wake, Atsushi; Uchida, Naoyuki; Taniguchi, Shuichi; Yamamoto, Go
- Abstract
Background: Mantle cell lymphoma is considered an aggressive B‐cell lymphoma. The optimal induction regimen remains controversial as no randomized controlled trial has compared the efficacy of different induction therapies. Method: Herein, we performed a retrospective analysis of the clinical characteristics of 10 patients who received induction treatment consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) and rituximab, bendamustine, and cytarabine (R‐BAC) at Toranomon Hospital between November 2016 and February 2022. Result: Although one patient discontinued R‐BAC therapy due to a rash, the other nine completed the scheduled chemotherapy. All patients achieved complete response, underwent high‐dose chemotherapy and autologous stem cell transplantation, and maintained complete remission with a median follow‐up of 15 months. Hematological adverse events (AEs) occurred in all patients; however, none developed documented infection. There were also no fatal non‐hematological AEs specific to R‐BAC. Conclusion: R‐CHOP/R‐BAC may be a good induction therapy for transplant‐eligible patients with mantle cell lymphoma.
- Subjects
MANTLE cell lymphoma; RITUXIMAB; CYTARABINE; STEM cell transplantation; ANTINEOPLASTIC combined chemotherapy protocols
- Publication
Cancer Medicine, 2023, Vol 12, Issue 11, p12548
- ISSN
2045-7634
- Publication type
Article
- DOI
10.1002/cam4.6114